Novartis looks to expand pipeline, focuses on long-term growth

BASEL, Switerland — Swiss drug maker Novartis will focus on innovation as part of a program for long-term growth, the company said Wednesday.

Novartis touted its research and development pipeline of 142 drugs in clinical trials, 35% of which are in phase 3 or undergoing regulatory review, as well as a plan to submit 30 more drugs for regulatory review by the end of 2012. The company also plans to continue investing in vaccine development.

“Novartis has leading businesses in fast-growing segments of health care, and by focusing on our strategic priorities, we are well-positioned to succeed in a rapidly changing healthcare environment,” CEO Joseph Jimenez said.

Other parts of the company’s strategy include its diversified drug portfolio and initiatives for increasing efficiencies in manufacturing, sales, marketing and procurement.

Login or Register to post a comment.